Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IYTIN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2024043319A1 1
|
|||||
| Synonyms |
WO2024043319A1 WO2024043319A1 1
Click to Show/Hide
|
|||||
| Organization |
EISAI R&D MANAGEMENT CO., LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
#84.7
|
Antibody Info | ||||
| Antigen Name |
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)
|
Antigen Info | ||||
| Payload Name |
WO2024043319A1 1 payload
|
Payload Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.076 nM | Positive CEACAM6 expression (CEACAM6 +++/++) | ||
| Method Description |
In vitro cytotoxicity of ADCs in AsPC-1 cells.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | AsPC-1 cells | CVCL_0152 | ||
